XTL Biopharma files to raise $40m on Nasdaq
In a citizens petition, Teva asked the FDA not to approve new multiple sclerosis treatments until it refers them to an advisory committee.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has filed a citizens petition with the US Food and Drug Administration (FDA) not to approve any new drugs for multiple sclerosis until their safety risks have been evaluated by outside advisers, the US media reports. Teva's multiple sclerosis drug, Copaxone, has billions of dollars in annual sales.
"Dow Jones News Wire" reports that Teva's petition targets Biogen Idec Inc. (Nasdaq: BIIB), which expects an FDA decision by late March on Biogen's application to market a new multiple sclerosis treatment, known as BG-12, an orally administered pill that analysts expect will be a formidable competitor to the injected Copaxone.
In the petition, filed on December 31, 2012, Teva asked the FDA not to approve any new multiple sclerosis drugs until the FDA refers them to an advisory committee for evaluation. Advisory committees sometimes review new drug applications to provide guidance to the agency.
Teva said it was important for the FDA to consult outside advisers' evaluations of any safety dangers, in light of risks that have emerged after multiple sclerosis treatments were approved in recent years, including Biogen's own Tysabri multiple sclerosis treatment. Tysabri was taken off the market shortly after its 2004 launch after some patients experienced a serious brain infection, and reintroduced in 2006 with a patient-monitoring plan.
Teva said in its petition that BG-12 'may be associated with other serious safety risks' including the potential risk for kidney-related problems. Teva cited a publicly accessible website containing animal toxicology data suggesting that kidney changes were seen in animals after they received BG-12's active ingredient, dimethyl fumarate, in studies. The website stated that the relevance of these findings to humans isn't known, according to the Teva petition."
Biogen spokeswoman Kate Niazi-Sai is quoted by the US media as saying that the company was confident in the clinical data supporting BG-12's safety and efficacy, and the regulatory review appears to be on track. It adds that results of a late-stage clinical trial of BG-12 published last year in the New England Journal of Medicine showed the incidence of kidney-related adverse events was similar between those receiving BG-12 and those on a placebo, and that rhere were no cases of kidney failure classified by researchers as serious adverse events.
"Dow Jones News Wire" quotes Teva spokeswoman Denise Bradley as saying that the petition was intended to bring to light important points "to protect the safety of patients," and that Teva wanted to ensure "that appropriate safeguards are implemented to maintain an acceptable risk- benefit profile" for any new multiple sclerosis drug.
FDA spokeswoman Sandy Walsh said the agency would review the petition.
Published by Globes [online], Israel business news - www.globes-online.com - on January 10, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.